Form 4: Candel Therapeutics CFO Sells Shares to Cover Tax Obligations

Charles Schoch, Interim CFO of Candel Therapeutics, sold 8,897 shares of common stock on July 11, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On July 11, 2024, Charles Schoch, the Interim CFO of Candel Therapeutics, sold 8,897 shares of the company's common stock.
• The sale was executed at a price of $5.9734 per share.
• This transaction was conducted to cover tax withholding obligations associated with the vesting and settlement of restricted stock units, as mandated by the company's sell-to-cover policy.
• Following the transaction, Schoch directly owns 72,404 shares of Candel Therapeutics.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the transaction is a routine sale to cover tax obligations and doesn't necessarily indicate a change in the executive's confidence in the company.

Positives

• The sale was part of a pre-existing company policy to cover tax obligations, indicating standard corporate governance.

Industry Context

Sales to cover tax obligations are a common practice among corporate executives receiving stock-based compensation. This filing provides transparency into such transactions.

Stakeholder Impact

• The sale has a minimal impact on shareholders as it is a small percentage of the total outstanding shares and is related to tax obligations.

Key Dates